Videos

In the second installment of this series, Ryan A. Hankins, MD, and Sean P. Collins, MD, PhD, provide insights on the multidisciplinary approach to treating patients with prostate cancer and discuss the roles of urologists and radiation oncologists.

“The real immediate use case is that this biomarker can be an adjunct, or it can be something to assist in making the shared decision making with patients [with prostate cancer],” says Daniel E. Spratt, MD.

“Burnout is the end stage of unmanaged stress in the workplace,” says Diana Londoño, MD.

Digging into the logistics of advanced prostate cancer management, keynote speakers consider challenges faced with the electronic systems used to request or order therapy.

Switching their focus to the treatment armamentarium, expert panelists reflect on selection and sequencing of therapy for patients with advanced prostate cancer.

"We've been focused on improving the quality of care around ureteroscopy for kidney stones, especially around a post operative emergency department visits," says Khurshid R. Ghani, MD.

"It's been pretty consistent that our second-year urology residents are really suffering," says Amanda C. North, MD.

"It could identify about 2/3 of men that normally we'd be recommending hormone therapy would appear to have no benefit from hormone therapy," says Daniel E. Spratt, MD.

A brief overview of how and when providers incorporate urodynamic testing as part of the diagnostic workup for OAB.

Panelists further expand on the typical clinical characteristics of patients with OAB who they see in their practice, common signs and symptoms, and potential differential diagnoses.

"As a result of this work, we came to the conclusion that maybe if you are going to stent someone, you should try and keep the stent time at a minimum of 4 or 5 days," says Khurshid R. Ghani, MD.

“I am lucky to work for a health care system that believes in serving the patients of the Bronx,” says Amanda C. North, MD.

"We're currently putting together... a toolkit that we can give to urologists and other providers in the community to help counsel their patients on some of the different avenues that they can go down to find more affordable medications," says Brian Cortese.

“Men with and without retention all do very well from the voiding standpoint with relatively low rates of complications,” says Claire S. Burton, MD.

“Learning how to disengage from stuff that can be pretty toxic and engaged in the stuff that's most meaningful, I think makes our lives better,” says Amanda C. North, MD.

"Right now, the longest-term studies are the WATER trials, which have published 5-year outcomes. But we know that a subset of men will require retreatment over time," says Claire S. Burton, MD.

Focused discussion on the quality of training and onboarding of physicians who manage advanced prostate cancer within a variety of institutions and settings.

Key opinion leaders in urology share their credentials and highlight the general structure of their institution in regard to prostate cancer management.

“I couldn't change the fact that it was going to be a few months until I had help. But I could change my own response to the situation,” says Amanda C. North, MD.

“One of the things we do is communicate with our teams and help them with some guidance about how to make decisions about which patients can potentially be treated with alternative approaches,” says Hamid Emamekhoo, MD.

"What we found is that those with acute urinary retention took longer to ultimately pass their trial without a catheter, meaning that they were voiding without the use of any catheterization," says Claire S. Burton, MD.

Experts begin their panel discussion on OAB by describing the typical diagnostic process and initial conversations that they have with patients suspected of having the condition.

Urologist Benjamin Brucker, MD, urogynecologist Eman Elkadry, MD, and nurse practitioner Jenna Horton, NP introduce themselves, outline their credentials, and briefly describe the patients with overactive bladder (OAB) who they typically see in their clinical practice.

“Because this was the largest trial ever of testosterone replacement therapy, although the primary point of the trial was cardiovascular safety, we embedded within the trial several efficacy and other sub studies,” says A. Michael Lincoff, MD.

“There are real, tangible consequences when we prescribe medications to our patients, not just the [adverse] effects studied in clinical trials,” says Brian Cortese.

“I think one of the hottest topics for advocacy right now relates to reimbursement for telemedicine,” says Amanda C. North, MD.

“We are now doing more testing on the RNA side,” says Brittany M. Szymaniak, PhD, CGC.

“For this population of patients…testosterone replacement therapy does appear to be safe from a cardiovascular standpoint,” says A. Michael Lincoff, MD.

"The Inflation Reduction Act could impact the livelihoods of a lot of patients by reducing their annual out-of-pocket costs," says Brian Cortese.

"In 2021, we were finally able to demonstrate a statistically significant difference in burnout between men and women in urology with women having much higher burnout rates," says Amanda C. North, MD.